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Abstract
We examined whether the interaction of baseline stimulant use, assessed by urine drug tests, and 
type of serious mental illness (SMI) diagnosis predicted stimulant use in a trial of contingency 
management (CM). The interaction between baseline stimulant use and SMI diagnoses was 
significant in the overall sample (p=0.002) when controlling for the main effects of treatment 
condition, baseline stimulant use, and SMI diagnosis. Similar results were also found within the 
CM sample. Individuals with bipolar disorder were more or less likely, depending on their baseline 
stimulant-drug test results, to use stimulants during treatment compared to those with other SMI 
diagnoses.
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1. Introduction
Approximately 1.5 million Americans report stimulant drug use, including cocaine, 
amphetamine, and methamphetamine yearly (Substance Abuse and Mental Health Services 
Administration, 2015). Twenty-five percent of cocaine users have a co-occurring serious 
mental illness (SMI) such as major depression, bipolar, or schizophrenia-spectrum disorders 
(Falck, Wang, Siegal, Carlson, 2004). These individuals are at an increased risk for 
emergency room visits (Nicosia, Pacula, Kilmer, Lundberg, Chiesa, 2009) and unstable 
housing (US Department of Housing and Urban Development, 2010).
Contingency management (CM) is an intervention that provides tangible reinforcers when 
individuals demonstrate drug abstinence, and is an effective treatment for stimulant drug use 
(Dutra et al., 2008). CM is associated with reduced substance use in adults with SMI 
(McDonell et al., 2013; Weiss et al., 2007). We found that outpatients with co-occurring 
stimulant use disorders and SMI receiving CM were two and a half times more likely to 
submit stimulant-negative results during treatment relative to controls (McDonell et al., 
2013). Several other studies have found that CM is an effective treatment for stimulant use in 
those with psychiatric problems (Gonzalez, Feingold, Oliveto, Gonsai, Kosten, 2003; Lester 
et al., 2007; McNamara, Schumacher, Milby, Wallace, Usdan, 2001; Milby et al., 2000; 
Shaner et al., 1997).
Less is known about the predictors of treatment outcomes in those with co-occurring 
disorders receiving CM. We previously found that a baseline stimulant-positive urine sample 
and higher psychological symptoms, not SMI diagnosis, were associated with a shorter 
duration of abstinence during CM (Angelo et al., 2013). In non-SMI populations, stimulant-
positive pre-treatment drug test is a robust predictor of CM outcomes (Petry, Barry, Alessi, 
Rounsaville, Carroll, 2012; McDonell et al., 2017). The relationship between psychiatric 
symptoms or diagnosis and CM treatment response has been less consistent. For instance, 
one study found that in CM, psychiatric symptoms were not associated with longest duration 
of abstinence (Weinstock, Alessi, Petry, 2007). Although not a CM study, Compton and 
colleagues (2003) found that diagnosis of major depression predicted poor treatment 
outcomes for alcohol use compared to other psychiatric disorders. Because no previous 
study had investigated the interaction of pre-treatment drug use and SMI diagnosis, we 
analyzed data from a CM trial (N=176) targeting stimulant use to determine if the 
interaction between baseline stimulant use and type of SMI predicted stimulant drug 
abstinence.
2. Methods
2.1. Participants
Participants were 176 adults with SMI and stimulant dependence in a randomized trial of 
CM for stimulant abstinence. Participants received treatment-as-usual (TAU) and were 
randomized to 12-weeks of CM for stimulant abstinence (n=91) or reinforcers for providing 
urine samples (non-contingent control [NC], n=85) (McDonell et al., 2013). SMI diagnoses 
were major depression (CM n=26, 29%; NC n=21, 25%), bipolar (CM n=30, 33%; NC 
n=30, 35%), and schizophrenia-spectrum disorders (CM n=35, 39%; NC n=34, 40%). 
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Written informed consent was obtained and the study was approved by the university 
Institutional Review Board.
2.2. Measures
Researchers administered the Mini International Neuropsychiatric Interview (MINI) major 
depressive episode, (hypo) manic episode, psychotic disorders, and drug and alcohol 
dependence and abuse diagnostic sections (Sheehan et al., 1998). Urine samples were tested 
for stimulant drugs using Integrated E-Z Split Key® cups (amphetamines=1,000 ng/mL, 
methamphetamines=1,000 ng/mL, and benzoylecgonine [cocaine]=300 ng/mL (Innovacon, 
Inc, San Diego, CA.), at baseline and three times per week during treatment.
2.3. Treatment Conditions
TAU included mental health (e.g., medication and case management), addiction (e.g., 
counseling), and vocational services. CM participants drew for tokens that represented 
different prizes (50% read “good job” valued at $0, 41.8% read “small” valued at $1, 0.8% 
read “large” valued at $20, 0.2% read “jumbo” valued at $80) for each stimulant-negative 
sample submitted. Participants earned prize draws for stimulant-negative urine samples. An 
additional draw was added for each week of continued stimulant abstinence, and a bonus 
draw was provided for abstinence from other substances. No prizes were given for stimulant-
positive or missing samples. The NC group received TAU and draws for each urine sample 
submitted even if results indicated stimulant use. The number of prize draws given to NC 
participants was equal to the average number of prize draws received by the CM participants 
in the previous week.
2.4. Statistical Analysis
Investigators descriptively analyzed the interaction of SMI diagnosis (major depression, 
bipolar, schizophrenia-spectrum disorders) and baseline stimulant use in both treatment 
conditions (CM, NC). Based on these findings and consistent with the parent study and other 
CM trials, we used generalized estimating equations ([GEE]; McPherson, Barbosa-Leiker, 
McDonell, Howell, Roll, 2013; Twisk, 2004) to determine whether baseline stimulant use; 
SMI diagnosis; treatment condition; and the interaction of baseline stimulant use and SMI 
diagnosis were associated with the stimulant-positive results (1=yes, 0=no) during treatment 
(up to 36 tests). Participants were excluded from the analyses if they had less than two 
measurements. Missing data was 1997/3276 in the CM group and 1525/3060 in the NC 
condition. Two separate GEE analyses were conducted: the overall sample controlling for 
treatment conditions and another was within the CM condition only (n=91). All possible 
pairwise comparison tests were conducted on the interaction term using the Bonferroni 
correction to avoid an inflated alpha rate. Results were reported as odds ratios (OR). 
Significance was p<.05 with 95% confidence intervals (CI). Analyses were conducted in 
SPSS 24.0 and post-hoc analyses performed in Stata 12.0 (StataCorp, College Station, TX).
3. Results
Figure 1 displays results of descriptive analyses of the interaction of SMI diagnosis and 
baseline stimulant use across the treatment period. After controlling for treatment conditions 
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(χ2 (1) =11.83, p=0.001), baseline stimulant use (χ2 (1) =58.84, p=0.001), and SMI 
diagnosis (χ2 (2) =0.86, p=0.65) in the randomized sample (N=176), the interaction of 
baseline stimulant use and SMI diagnosis (χ2 (2) =12.52, p=0.002) was associated with 
stimulant use during treatment.
Post-hoc analyses revealed that among participants with stimulant-negative results at 
baseline, those with schizophrenia-spectrum disorders were 3.40 times (95% CI=1.33–8.70) 
more likely than those with bipolar disorder to submit stimulant-positive samples during 
treatment. Among those with stimulant-positive results at baseline, participants diagnosed 
with bipolar disorder were 2.24 times (95% CI=1.06–4.75) more likely than those with 
major depression to submit stimulant-positive samples. Compared to participants who were 
stimulant-negative at baseline, participants who were stimulant-positive at baseline were 
more likely to submit stimulant-positive treatment samples for each SMI diagnoses; major 
depression (OR=5.12, 95% CI: 2.23–11.79), bipolar (OR=26.54, 95% CI: 10.38–81.45), 
schizophrenia-spectrum (OR=4.01, 95% CI: 1.96–8.18) disorders.
Within the CM condition, after controlling for baseline stimulant use (χ2 (1) =21.99, 
p=0.001), and SMI diagnosis (χ2 (2) =0.25, p=0.88), the interaction of baseline stimulant 
use and SMI diagnosis (χ2 (2) =12.09, p=0.002) was a significant predictor of treatment 
outcomes. In post-hoc analyses, individuals with schizophrenia-spectrum disorders with 
stimulant-negative results at baseline were 11.18 times (95% CI=1.53–81.26) more likely to 
submit stimulant-positive samples during treatment compared to participants with bipolar 
disorder. Among those with stimulant-positive results at baseline, individuals with 
schizophrenia-spectrum disorders were less likely (OR=0.20, 95% CI=0.06–0.63) than 
participants with bipolar disorder to submit stimulant-positive samples. Participants who 
were stimulant-positive at baseline were more likely than those who were not to submit 
stimulant-positive samples within SMI diagnoses of major depression (OR=4.13, 95% CI: 
0.98–17.36) and bipolar disorder (OR=77.62, 95% CI: 10.30–584.93).
4. Discussion
Individuals with bipolar disorder who used stimulants at baseline had the poorest treatment 
outcomes, relative to those with other SMI diagnoses, while those with bipolar disorder who 
had not used stimulants at baseline responded most favorably to treatment (Figure 1). These 
results identify subgroups that may not respond to standard co-occurring disorder treatment 
and more specifically, CM for stimulant abstinence.
In a separate trial of CM targeting alcohol use in adults with SMI, we found that among 
those with major depression the likelihood of submitting alcohol-negative urine samples was 
dependent on pre-treatment drinking levels (Oluwoye et al., 2017). Differences in the results 
of these two studies are possibly an artifact of the different types of substance use; however, 
both suggest that the assessment of drug use severity and SMI diagnosis are important when 
predicting CM efficacy.
Limitations include participant recruitment from one agency, possible diagnostic errors, and 
missing data due to attrition. The recruitment site was similar to other community mental 
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health centers, assurances (i.e., trained research personnel validating diagnoses) preventing 
diagnostic errors were made, and our statistical methodology (i.e., GEE) accounted for 
missing data by using all available pairs in analyses. We did not examine psychological 
distress, contrary to findings in our previous study (Angelo et al., 2013) which may explain 
some variance in outcomes. However, we chose to use SMI diagnosis instead of 
psychological distress due to diagnosis being a more clinically meaningful measure that has 
been found to be a significant predictor in previous studies (Compton, Cottler, Jacobs, Ben-
Abdallah, Spitznagel, 2003; Weinstock, Alessi, Petry, 2007).
Findings provide initial evidence that outpatients with SMI differ in terms of their response 
to co-occurring stimulant disorders treatment, based on the interaction of pre-treatment 
stimulant use and type of SMI diagnosis. Importantly, these factors can be easily assessed 
upon entering treatment using urine drug tests and diagnostic interviews, providing a 
feasible way to predict treatment response and a potential opportunity to tailor treatment to 
specific subgroups of individuals with co-occurring disorders.
Acknowledgments
Funding
This work was supported by the National Institute on Drug Abuse R01 DA022476-01; the NIDA had no further role 
in study design; in the collection, analysis and interpretation of data; in the writing of the report; or in the decision 
to submit the paper for publication.
SM and JR have received research funding from the Bristol-Myers Squibb Foundation. SM has also received 
funding from the Orthopedic Specialty Institute. This funding is in no way related to the investigation reported here.
References
Angelo FN, McDonell MG, Lewin MR, Srebnik D, Lowe J, Roll J, Ries R. Predictors of stimulant 
abuse treatment outcomes in severely mentally ill outpatients. Drug Alcohol Depend. 2013; 
131:162–165. DOI: 10.1016/j.drugalcdep.2012.11.017 [PubMed: 23273776] 
Compton WM III, Cottler LB, Jacobs JL, Ben-Abdallah A, Spitznagel EL. The role of psychiatric 
disorders in predicting drug dependence treatment outcomes. Am J Psychiatry. 2003; 160:890–895. 
doi: https://doi.org/10.1176/appi.ajp.160.5.890. [PubMed: 12727692] 
Dutra L, Stathopoulou G, Basden SL, Leyro TM, Powers MB, Otto MW. A meta-analytic review of 
psychosocial interventions for substance use disorders. Am J Psychiatry. 2008; 165:179–187. doi: 
https://doi.org/10.1176/appi.ajp.2007.06111851. [PubMed: 18198270] 
Falck RS, Wang J, Siegal HA, Carlson RG. The prevalence of psychiatric disorder among a 
community sample of crack cocaine users: An exploratory study with practical implications. J Nerv 
Ment Dis. 2004; 192:503–507. DOI: 10.1097/01.nmd.0000131913.94916.d5 [PubMed: 15232321] 
Gonzalez G, Feingold A, Oliveto A, Gonsai K, Kosten TR. Comorbid major depressive disorder as a 
prognostic factor in cocaine-abusing buprenorphine-maintained patients treated with desipramine 
and contingency management. Am J Drug Alcohol Abuse. 2003; 29:497–514. [PubMed: 14510037] 
McDonell MG, Leickly E, McPherson S, Skalisky J, Srebnik D, Angelo F, Ries RK. A randomized 
controlled trial of ethyl glucuronide-based contingency management for outpatients with co-
occurring alcohol use disorders and serious mental illness. Am J Psychiatry. 2017; 174:370–377. 
doi: doi.org/10.1176/appi.ajp.2016.16050627. [PubMed: 28135843] 
McDonell MG, Srebnik D, Angelo F, McPherson S, Lowe JM, Sugar A, Ries RK. Randomized 
controlled trial of contingency management for stimulant use in community mental health patients 
with serious mental illness. Am J Psychiatry. 2013; 170:94–101. doi: https://doi.org/10.1176/
appi.ajp.2012.11121831. [PubMed: 23138961] 
Oluwoye et al. Page 5
Psychiatry Res. Author manuscript; available in PMC 2019 February 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
McNamara C, Schumacher JE, Milby JB, Wallace D, Usdan S. Prevalence of nonpsychotic mental 
disorders does not affect treatment outcome in a homeless cocaine-dependent sample. Am J Drug 
and Alcohol Abuse. 2001; 27:91–106. doi: http://dx.doi.org/10.1081/ADA-100103120. [PubMed: 
11373038] 
McPherson S, Barbosa‐Leiker C, McDonell M, Howell D, Roll J. Longitudinal missing data strategies 
for substance use clinical trials using generalized estimating equations: an example with a 
buprenorphine trial. Hum Psychopharmacology: Clinical and Experimental. 2013; 28:506–515.
Milby JB, Schumacher JE, McNamara C, Wallace D, Usdan S, McGill T, et al. Initiating abstinence in 
cocaine abusing dually diagnosed homeless persons. Drug and Alcohol Depend. 2000; 60:55–67. 
doi: https://doi.org/10.1016/S0376-8716(0080008-3). 
Nicosia, N., Pacula, RL., Kilmer, B., Lundberg, R., Chiesa, J. The economic cost of methamphetamine 
use in the United States. Santa Monica, CA: RAND Health; 2009. 2005. No MG-829-MPF/
NIDARetrieved August 29, 2017, from http://www.dtic.mil/dtic/tr/fulltext/u2/a498655.pdf
Oluwoye, O., Leickly, E., Skalisky, J., McPherson, S., Hirchak, K., Srebnik, D., Roll, JM., Ries, RK., 
McDonell, MG. Serious mental illness in heavy drinkers is associated with poor treatment 
outcomes in outpatients with co-occurring disorders; International Journal of Mental Health and 
Addiction. 2017. p. 1-8.doi: https://doi.org/10.1007/s11469-017-9821-4
Petry NM, Barry D, Alessi SM, Rounsaville BJ, Carroll KM. A randomized trial adapting contingency 
management targets based on initial abstinence status of cocaine-dependent patients. Journal of 
consulting and clinical psychology. 2012; 80:276. [PubMed: 22229758] 
Shaner A, Roberts LJ, Eckman TA, Tucker DE, Tsuang JW, Wilkins JN, et al. Monetary reinforcement 
of abstinence from cocaine among mentally ill patients with cocaine dependence. Psychiatr Serv. 
1997; 48:807–810. doi: https://doi.org/10.1176/ps.48.6.807. [PubMed: 9175190] 
Sheehan DV, Lecrubier Y, Sheehan KH, Amorim P, Janavs J, Weiller E, Dunbar GC. The mini-
international neuropsychiatric interview (MINI): The development and validation of a structured 
diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry. 1998; 59:22–53.
Substance Abuse and Mental Health Services Administration. Behavioral health trends in the united 
states: Results from the 2014 national survey on drug use and health. 2015. HHS publication no 
SMA 15-4927, NSDUH series H-50Retrieved August 29, 2017, from https://www.samhsa.gov/
data/sites/default/files/NSDUH-FRR1-2014/NSDUH-FRR1-2014.htm
Twisk JW. Longitudinal data analysis. A comparison between generalized estimating equations and 
random coefficient analysis. European journal of epidemiology. 2004; 19:769–776. [PubMed: 
15469034] 
US Department of Housing and Urban Development. The 2009 annual homeless assessment report to 
congress. Washington DC: Office of community planning and development, HUD; 2010. 
Retrieved August 29, 2017, from https://www.huduser.gov/Publications/pdf/
2009_homeless_508.pdf
Weinstock J, Alessi SM, Petry NM. Regardless of psychiatric severity the addition of contingency 
management to standard treatment improves retention and drug use outcomes. Drug and Alcohol 
Depend. 2007; 87:288–296.
Weiss RD, Griffin ML, Kolodziej ME, Greenfield SF, Najavits LM, Daley DC, Hennen JA. A 
randomized trial of integrated group therapy versus group drug counseling for patients with bipolar 
disorder and substance dependence. Am J Psychiatry. 2007; 164:100–107. doi: https://doi.org/
10.1176/ajp.2007.164.1.100. [PubMed: 17202550] 
Oluwoye et al. Page 6
Psychiatry Res. Author manuscript; available in PMC 2019 February 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Highlights
• The interaction of baseline stimulant use and type of SMI predicted stimulant 
use.
• Results in overall sample were replicated in the contingency management 
only group.
• Responses differed for those with bipolar disorder depending on baseline use.
• Tailored treatment among individuals with co-occurring disorders is needed.
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Figure 1. 
Percentage of stimulant-positive urine samples during treatment differs based on the 
interaction of baseline stimulant use and serious mental illness diagnoses.
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